17 September 2021
Thalassa Holdings Ltd
(Reuters: THAL.L, Bloomberg: THAL:LN)
("Thalassa", "THAL" or the "Company")
London Medical Laboratory Limited ("LML") investment update
This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.
The Board of Thalassa wishes to report that the Company has exited its investment in LML, as detailed in RNS 6319N of 2 February 2021.
Mr Tim Donell, CFO of Thalassa will remain on the Board of LML.
Commenting, Mr Soukup stated, "The divestiture of Thalassa's holding in LML was, unfortunately, caused by unforeseen circumstances and has nothing to do with our view of LML's outstanding prospects. We have enjoyed working with Dr. Rankin and the LML team and do not rule out a potential participation in LML at a later date, as circumstances allow."
END
| Enquiries: |
|
| Thalassa Holdings Ltd |
|
| Duncan Soukup, Chairman | +33 (0)6 78 63 26 89 |
Note to Editors:
About Thalassa
Thalassa Holdings Ltd. is a holding company with various interests across several industries which currently include, Fintech, Robotics, Leisure & Entertainment and Security & Access Control.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.